Drug Profile


Alternative Names: '081; 961081; Batefenterol succinate; GSK-961081; GSK-961081A; GSK-961081D; TD-5959

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Theravance
  • Developer GlaxoSmithKline
  • Class Biphenyl compounds; Bronchodilators; Carbamates; Carboxylic acids; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic obstructive pulmonary disease

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-obstructive-pulmonary-disease(Combination therapy, In volunteers) in United Kingdom (Inhalation, Powder)
  • 01 Jul 2016 GlaxoSmithKline completes a phase II trial for Chronic obstructive pulmonary disease in USA, Germany and South Africa (NCT02570165)
  • 01 Jun 2016 GlaxoSmithKline completes a phase I trial in healthy volunteers (alone and combination with fluticasone) in UK (NCT02666287)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top